Ultrase MT12 and Ultrase MT20 in the treatment of exocrine pancreatic insufficiency in cystic fibrosis: safety and efficacy.

Konstan, M W; Stern, R C; Trout, J R; Sherman, J M; Eigen, H; Wagener, J S; Duggan, C; Wohl, M E B; Colin, P

Konstan, M W; Stern, R C; Trout, J R; Sherman, J M; Eigen, H; Wagener, J S; Duggan, C; Wohl, M E B; Colin, P.

Affiliation

Konstan MW; Rainbow Babies and Children's Hospital, Cleveland, OH 44106, USA. michael.konstan@case.edu

Aliment Pharmacol Ther ; 20(11-12): 1365-71, 2004 Dec.

Article in En | MEDLINE | ID: mdl-15606399

Subject(s)

Cystic Fibrosis/complications; Exocrine Pancreatic Insufficiency/drug therapy; Gastrointestinal Agents/administration & dosage; Lipase/administration & dosage; Adolescent; Adult; Aged; Child; Cross-Over Studies; Double-Blind Method; Exocrine Pancreatic Insufficiency/etiology; Female; Gastrointestinal Agents/adverse effects; Humans; Lipase/adverse effects; Male; Middle Aged

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Exocrine Pancreatic Insufficiency / Gastrointestinal Agents / Cystic Fibrosis / Lipase Type of study: Clinical_trials / Etiology_studies Limits: Adolescent / Adult / Aged / Child / Female / Humans / Male / Middle aged Language: En Journal: Aliment Pharmacol Ther Journal subject: FARMACOLOGIA / GASTROENTEROLOGIA / TERAPIA POR MEDICAMENTOS Year: 2004 Type: Article Affiliation country: United States

Search on Google

XML

PubMed Links